MY189576A - Omega-3 fatty acid ester compositions - Google Patents

Omega-3 fatty acid ester compositions

Info

Publication number
MY189576A
MY189576A MYPI2014002698A MYPI2014002698A MY189576A MY 189576 A MY189576 A MY 189576A MY PI2014002698 A MYPI2014002698 A MY PI2014002698A MY PI2014002698 A MYPI2014002698 A MY PI2014002698A MY 189576 A MY189576 A MY 189576A
Authority
MY
Malaysia
Prior art keywords
omega
fatty acid
compositions
acid ester
administering
Prior art date
Application number
MYPI2014002698A
Other languages
English (en)
Inventor
Frederick Sancilio
Peter Persicaner
Janice Cacace
Mohand Dahim
Original Assignee
Micelle Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47998519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY189576(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Micelle Biopharma Inc filed Critical Micelle Biopharma Inc
Publication of MY189576A publication Critical patent/MY189576A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
MYPI2014002698A 2012-03-30 2013-03-11 Omega-3 fatty acid ester compositions MY189576A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261618161P 2012-03-30 2012-03-30
PCT/US2013/030211 WO2013148136A1 (en) 2012-03-30 2013-03-11 Omega-3 fatty acid ester compositions

Publications (1)

Publication Number Publication Date
MY189576A true MY189576A (en) 2022-02-17

Family

ID=47998519

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2014002698A MY189576A (en) 2012-03-30 2013-03-11 Omega-3 fatty acid ester compositions

Country Status (19)

Country Link
US (9) US9302016B2 (enExample)
EP (2) EP3072510B1 (enExample)
JP (1) JP6359517B2 (enExample)
KR (1) KR102193214B1 (enExample)
CN (2) CN109966279A (enExample)
AU (1) AU2013240427B2 (enExample)
CA (1) CA2867168A1 (enExample)
CO (1) CO7121328A2 (enExample)
DK (1) DK3072510T3 (enExample)
ES (1) ES2741560T3 (enExample)
HK (1) HK1204978A1 (enExample)
HR (1) HRP20191392T1 (enExample)
IL (3) IL249821B (enExample)
IN (1) IN2014DN08449A (enExample)
MX (1) MX359711B (enExample)
MY (1) MY189576A (enExample)
PT (1) PT3072510T (enExample)
RU (1) RU2633862C2 (enExample)
WO (1) WO2013148136A1 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2334295T (pt) 2008-09-02 2017-09-15 Amarin Pharmaceuticals Ie Ltd Composição farmacêutica compreendendo ácido eicosapentanoico e ácido nicotínico e métodos de utilização dos mesmos
CN107233337A (zh) 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
SI2424356T1 (en) 2009-04-29 2018-01-31 Armarin Pharmaceuticals Ireland Limited A stable pharmaceutical composition and procedures for its use
WO2010147994A1 (en) 2009-06-15 2010-12-23 Amarin Pharma, Inc. Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
MX2012003555A (es) 2009-09-23 2012-07-03 Amarin Corp Plc Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
NZ727980A (en) 2010-11-29 2018-08-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
CN104321055A (zh) 2012-01-06 2015-01-28 翁特拉制药公司 游离酸形式的ω-3多不饱和脂肪酸的富含dpa组合物
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
IN2014DN08449A (enExample) 2012-03-30 2015-05-08 Sancilio & Company Inc
EP3815684B1 (en) 2012-06-29 2024-09-04 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
WO2015011724A2 (en) 2013-07-22 2015-01-29 Kms Health Center Pvt Ltd A novel omega -3 fatty acid composition with a plant extract
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
WO2015066512A1 (en) * 2013-10-31 2015-05-07 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
WO2016046680A2 (en) * 2014-09-27 2016-03-31 Mohan M Alapati Compositions and methods for the treatment of liver metabolic diseases
MA40846A (fr) * 2014-10-10 2017-09-05 Sancilio & Company Inc Compositions d'acides gras et d'esters d'acides gras auto-micellisantes, ainsi que leur utilisation dans le traitement d'états pathologiques
MY185428A (en) * 2015-01-21 2021-05-19 Mochida Pharm Co Ltd Self-emulsifying composition of ?-3 fatty acid
MA41611A (fr) * 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
DE102015106095A1 (de) * 2015-04-21 2016-10-27 K. D. Pharma Bexbach Gmbh Neue Anwendung von Omega-3-Fettsäure(n)
WO2017033119A1 (en) * 2015-08-25 2017-03-02 Rao M Surya Compositions and methods for the treatment of liver metabolic diseases
CN106692973A (zh) * 2015-11-13 2017-05-24 深圳君圣泰生物技术有限公司 一种组合物及其用途、药物制剂
KR20180094516A (ko) * 2015-12-18 2018-08-23 애피뮨 리미티드 15-hepe를 포함하는 조성물 및 이를 사용하는 방법
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
AU2017232554B2 (en) * 2016-03-16 2020-05-14 Golden Omega Norway As Powders and tablets comprising omega-3 fatty acid derivatives and methods for their production
WO2018027278A1 (en) 2016-08-12 2018-02-15 Pharmako Biotechnologies Pty Limited Omega-3 compositions and methods relating thereto
US11351127B2 (en) 2016-09-21 2022-06-07 Avexxin As Pharmaceutical composition
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
CN108354919A (zh) * 2017-12-29 2018-08-03 广东海洋大学 一种用于提高抗氧化功能的不饱和脂肪酸组合物及其应用
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
ES2983568T3 (es) 2018-09-24 2024-10-23 Amarin Pharmaceuticals Ie Ltd Métodos para reducir el riesgo de eventos cardiovasculares en un sujeto
WO2020160216A1 (en) * 2019-02-01 2020-08-06 Mars, Incorporated Feline food composition
EP4009965A4 (en) 2019-08-08 2023-11-15 Swinburne University of Technology USES OF LONG-CHAIN POLYUNSATURATED FATTY ACIDS
EP4058141A4 (en) 2019-11-12 2023-11-22 Amarin Pharmaceuticals Ireland Limited METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT WITH Atrial fibrillation and/or atrial flutter
US20230126529A1 (en) 2020-03-12 2023-04-27 Fred D. Sancilio Docosahexaenoic acid and egg yolk containing composition suitable for sickle cell disease treatment
US20230398088A1 (en) * 2020-10-30 2023-12-14 The Trustees Of The University Of Pennsylvania Lipid Prophylactic Brain Injury Treatment
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513008A (en) 1982-07-30 1985-04-23 The Vinoxen Company, Inc. Virucidal compositions and therapy
US4992476A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Skin cleansing and moisturizing composition and method of using and preparing same
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
ATE90202T1 (de) 1989-02-16 1993-06-15 British Tech Group Wirkstoffabgabevorrichtung.
US5320798A (en) 1993-02-17 1994-06-14 Exxon Chemical Patents, Inc. Method for processing polyolefins at high shear rates
US5585192A (en) 1995-10-02 1996-12-17 Eastman Chemical Company Waterborne polyolefin adhesion promoter
KR100587551B1 (ko) * 1997-12-10 2006-06-08 싸이클로스포린 테라퓨틱스 리미티드 오메가-3 지방산 오일을 함유하는 약학 조성물
US6121210A (en) 1998-03-12 2000-09-19 Dap Products Inc. Foamable silicone oil compositions and methods of use thereof
IT1308613B1 (it) * 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
DE60020382T2 (de) 1999-09-21 2006-01-26 Skyepharma Canada Inc., Verdun Oberflächenmodifizierte teilchenförmige zusammensetzungen biologisch aktiver stoffe
NO313076B1 (no) 1999-12-28 2002-08-12 Pronova Biocare As Flytende n¶rings- og/eller nytelsesmiddel og fremgangsmåte for fremstilling derav
KR100441167B1 (ko) 2001-12-27 2004-07-21 씨제이 주식회사 마이크로에멀젼 예비 농축액 조성물
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
EP2368445A1 (en) 2002-06-18 2011-09-28 Martek Biosciences Corporation Stable Emulsions of Oils in Aqueous Solutions and Methods for Producing Same
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
AU2003279493B2 (en) 2002-10-25 2009-08-20 Foamix Pharmaceuticals Ltd. Cosmetic and pharmaceutical foam
CN1856294A (zh) 2003-08-25 2006-11-01 弗米克斯有限公司 渗透性药物泡沫
AU2004289353B2 (en) 2003-11-12 2011-02-10 Children's Medical Center Corporation Treatment and prevention of liver disease associated with parenteral nutrition (PN)
SE0303513D0 (sv) 2003-12-19 2003-12-19 Pronova Biocare As Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
JP2007526943A (ja) 2004-03-04 2007-09-20 エイチティーエル ハイ − テック リピッズ リミテッド 構造化されたトリグリセリド類およびそれを含むエマルション類
CA2572344A1 (en) 2004-07-01 2006-01-19 Schepens Eye Research Compositions and methods for treating eye disorders and conditions
WO2006010370A1 (de) 2004-07-22 2006-02-02 Aquanova German Solubilisate Technologies (Agt) Gmbh Solubilisate von ätherischen ölen und anderen stoffen
ITRM20040395A1 (it) * 2004-08-03 2004-11-03 Sigma Tau Ind Farmaceuti Composizione comprendente statine e acidi grassi omega 3.
JP2008516890A (ja) 2004-08-06 2008-05-22 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 新規なフェノフィブラート製剤および関連治療方法
US7642287B2 (en) 2004-08-06 2010-01-05 Transform Pharmaceuticals, Inc. Statin pharmaceutical compositions and related methods of treatment
JP4943849B2 (ja) * 2004-08-18 2012-05-30 持田製薬株式会社 ゼリー組成物
JPWO2006022291A1 (ja) 2004-08-27 2008-05-08 千寿製薬株式会社 ドライアイ治療用点眼液
US8324276B2 (en) 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
EA200701913A1 (ru) 2005-03-08 2008-08-29 Релайэнт Фармасьютикалз, Инк. Лечение статином, омега-3 жирными кислотами и их комбинированным продуктом
US20060223737A1 (en) 2005-03-25 2006-10-05 L'oreal Foaming O/W emulsion and use thereof in cosmetics
US9968120B2 (en) 2006-05-17 2018-05-15 Dsm Nutritional Products Ag Homogenized formulations containing microcapsules and methods of making and using thereof
JP2009510115A (ja) 2005-09-29 2009-03-12 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ｈｔ２ａセロトニン受容体に関連する疾患の治療に有用な５−ｈｔ２ａセロトニン受容体モジュレーターの薬学的組成物
US20070104779A1 (en) 2005-11-07 2007-05-10 Rongen Roelof M Treatment with omega-3 fatty acids and products thereof
CA2628305C (en) * 2005-11-11 2014-05-06 Mochida Pharmaceutical Co., Ltd. Jelly composition
BRPI0618870A2 (pt) 2005-11-22 2011-09-13 Nestec Sa emulsão de óleo-em-água e seu uso para a distribuição de funcionalidade
EP2364701A1 (en) 2005-12-20 2011-09-14 Cenestra, Llc Omega-3 fatty acid formulations
US20080058418A1 (en) * 2006-09-06 2008-03-06 The Coca-Cola Company Stable polyunsaturated fatty acid emulsions and methods for inhibiting, suppressing, or reducing degradation of polyunsaturated fatty acids in an emulsion
CN101553136A (zh) * 2006-09-06 2009-10-07 可口可乐公司 稳定的多不饱和脂肪酸乳液及用于防止、抑制或降低多不饱和脂肪酸在乳液中降解的方法
EP2098222A4 (en) 2006-10-31 2012-12-26 Kaneka Corp GRANULAR COMPOSITION CONTAINING PHYSIOLOGICALLY ACTIVE SUBSTANCE AND METHOD FOR PRODUCING THE SAME
US20080306154A1 (en) 2006-11-03 2008-12-11 My Svensson Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids
US20090011012A1 (en) 2007-07-06 2009-01-08 Baum Seth J Fatty acid compositions and methods of use
US20090182049A1 (en) 2008-01-16 2009-07-16 Joar Arild Opheim Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans
GB0813599D0 (en) * 2008-07-24 2008-09-03 Pharma Marine As Method
US20100062057A1 (en) 2008-09-10 2010-03-11 Pronova BioPharma Norge AS. Formulation
CN101380358B (zh) 2008-10-14 2012-12-19 沈阳药科大学 精制紫苏籽油脂肪乳注射液及制备工艺
EP2405903B1 (en) 2009-03-09 2024-04-10 Basf As Compositions comprising a fatty acid oil mixture and a free fatty acid, and methods and uses thereof
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
EP2429317B2 (en) 2009-04-17 2019-02-20 Natac Pharma, S.L. Compositions rich in omega-3 fatty acids with a low content in phytanic acid
CN107233337A (zh) 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
EP2433630A4 (en) 2009-05-22 2014-01-08 Mochida Pharm Co Ltd SELF-EMULSIFIABLE COMPOSITION OF FATTY ACID 3
US9480645B2 (en) 2009-06-02 2016-11-01 Abbott Medical Optics Inc. Omega-3 oil containing ophthalmic emulsions
US20110045050A1 (en) 2009-08-24 2011-02-24 Atrium Medical Corporation Nanoemulsion formulations for direct delivery
EP2488022B1 (en) 2009-10-16 2018-01-10 Mochida Pharmaceutical Co., Ltd. Compositions
US9370493B2 (en) * 2009-10-23 2016-06-21 Pronova Biopharma Norge As Coated capsules and tablets of a fatty acid oil mixture
US8927043B2 (en) 2009-11-10 2015-01-06 Mycell Technologies Stabilized formulations of fatty acids
US20140017308A1 (en) * 2010-09-08 2014-01-16 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture, a free fatty acid, and a statin
WO2012032415A2 (en) 2010-09-08 2012-03-15 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form, a surfactant, and a statin
AR082930A1 (es) * 2010-09-08 2013-01-16 Pronova Biopharma Norge As Composiciones que comprenden una mezcla oleosa de acidos grasos, un tensioactivo y una estatina
US9415035B2 (en) 2010-09-17 2016-08-16 Maine Natural Health Company, Inc. Compositions containing omega-3 oil with an anti-inflammatory agent and uses thereof
WO2012037311A1 (en) 2010-09-17 2012-03-22 Maine Natural Health, Inc. Compositions containing omega-3 oil and uses thereof
CN104394850A (zh) 2012-02-16 2015-03-04 布莱特赛德创新有限公司 膳食和营养组合物及应用的方法
IN2014DN08449A (enExample) 2012-03-30 2015-05-08 Sancilio & Company Inc

Also Published As

Publication number Publication date
EP2830602A1 (en) 2015-02-04
ES2741560T3 (es) 2020-02-11
MX359711B (es) 2018-10-08
WO2013148136A1 (en) 2013-10-03
PT3072510T (pt) 2019-08-22
CN109966279A (zh) 2019-07-05
US9375490B2 (en) 2016-06-28
US20140348929A1 (en) 2014-11-27
US9364558B2 (en) 2016-06-14
EP2830602B1 (en) 2020-10-21
IL249821B (en) 2019-04-30
CN104321053A (zh) 2015-01-28
HK1204978A1 (zh) 2015-12-11
KR102193214B1 (ko) 2020-12-18
CO7121328A2 (es) 2014-11-20
IL249821A0 (en) 2017-02-28
IN2014DN08449A (enExample) 2015-05-08
US20140348930A1 (en) 2014-11-27
EP3072510B1 (en) 2019-05-08
CA2867168A1 (en) 2013-10-03
DK3072510T3 (da) 2019-08-12
MX2014011596A (es) 2015-07-06
JP6359517B2 (ja) 2018-07-18
US9302017B2 (en) 2016-04-05
US20150328326A1 (en) 2015-11-19
US20150328177A1 (en) 2015-11-19
US9364560B2 (en) 2016-06-14
RU2014141406A (ru) 2016-05-20
AU2013240427A1 (en) 2014-09-25
US20150328153A1 (en) 2015-11-19
US20150328327A1 (en) 2015-11-19
US9364561B2 (en) 2016-06-14
EP3072510A1 (en) 2016-09-28
AU2013240427B2 (en) 2017-08-03
RU2633862C2 (ru) 2017-10-18
US9370585B2 (en) 2016-06-21
US20150328178A1 (en) 2015-11-19
IL234814A (en) 2017-11-30
US20150328324A1 (en) 2015-11-19
US20150328325A1 (en) 2015-11-19
US9302016B2 (en) 2016-04-05
US9364562B2 (en) 2016-06-14
US9364559B2 (en) 2016-06-14
KR20140145597A (ko) 2014-12-23
JP2015514083A (ja) 2015-05-18
HRP20191392T1 (hr) 2019-12-27

Similar Documents

Publication Publication Date Title
MY189576A (en) Omega-3 fatty acid ester compositions
WO2014074552A3 (en) Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
WO2014004861A3 (en) Methods of treating pediatric metabolic syndrome
HK1198515A1 (en) Fatty acid compositions
HK1210417A1 (en) Compositions, methods and/or devices for prevention and/or treatment of dry eye disorders
WO2014005013A3 (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
NZ716730A (en) Methods, compositions, and devices for supplying dietary fatty acid needs
HK1206248A1 (en) Compositions of statins and omega-3 fatty acids
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
WO2014013335A3 (en) Concentration of omega-3 polyunsaturated fatty acids in krill oil
HK1202415A1 (en) Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of use thereof
WO2012013331A3 (en) Capsules of active pharmaceutical ingredients and polyunsaturated fatty acids for the treatment of prostate diseases
MX2020002238A (es) Composiciones de acidos grasos y ester de acido graso autoformadores de micelas y su uso en el tratamiento de patologias.
WO2014057362A3 (en) Omega -3 compositions
WO2014011895A3 (en) High solubility acid salts, intravenous dosage forms, nutrition supplementation and methods of use thereof
JP2014505702A5 (enExample)
NZ630210A (en) Nutritional compositions including rrr -alpha tocopherol and polyunsaturated fatty acids
WO2014165190A3 (en) Compositions comprising docosapentaenoic acid and methods of use
MX2015007436A (es) Forma de dosificacion oral solida de derivado de testosterona.
WO2014089511A3 (en) Administering compositions comprising docosapentaenoic acid
WO2014205109A3 (en) Compositions and methods for the treatment and management of steatosis in human liver
WO2011149766A3 (en) Lipid-tailored pharmaceutical agents
WO2013052433A3 (en) Methods and compositions for reducing food intake and body weight gain in animals
JP2017536367A5 (enExample)
CA2872488A1 (en) Dehydrated castor oil as an animal feed supplement